Intervention Study on Medication Reconciliation Among Pharmacists in Two Tertiary Hospitals in Nigeria

November 25, 2022 updated by: AKINNIYI AKINBIYI AJE, University of Ibadan
This study will assess the current practice of medication reconciliation among pharmacists in the selected institutions with a view to making an intervention to address gaps discovered

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Background information garnering will be done among the pharmacists in the two selected hospitals to collect data on current practice of medication reconciliation. Focus group discussion will be done in the intervention group so as to identify peculiarities of their practice and to provide the best approach to carrying out the intervention. Diabetes and hypertensive patients in medical outpatient clinic will be interviewed in order to assess current practice of medication reconciliation.

Intervention will be channeled towards addressing gaps discovered. University College Hospital, Ibadan, Oyo State will be the intervention group, while University of Ilorin Teaching Hospital, Kwara State will be the control group.

The effect of the intervention will be measured over time to ensure that medication reconciliation is implemented in the selected institutions.

Study Type

Interventional

Enrollment (Actual)

1000

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Nigeria
    • Kwara
      • Ilorin, Kwara, Nigeria
        • University of Ilorin Teaching Hospital
    • Oyo
      • Ibadan, Oyo, Nigeria, 2334
        • University College Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Participant has diabetes and/or hypertension
  • Registered pharmacists in the selected institutions

Exclusion Criteria:

  • Participants that are neither diabetic nor hypertensive
  • Unregistered pharmacists in the selected institutions

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Health Services Research
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Intervention arm

Seminar presentation will be done using the followings:

  1. Power point presentation on the following topics as it relates to medication reconciliation:

    1. Communication skill (with patients and also with other members of the healthcare team)
    2. Documentation of pharmaceutical care activities
    3. Medication history taking
    4. Drug therapy problems
    5. Medication reconciliation practice
  2. Case studies on medication reconciliation
  3. Role plays on medication reconciliation
Other: Medication reconciliation
Pre-post intervention
No Intervention: Control arm
Control group

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Medication reconciliation: Percentage unreconciled medications
Time Frame: 3 months
Percentage unreconciled medications
3 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Ibadan

Investigators

  • Study Director: TITILAYO O FAKEYE, PhD, University of Ibadan

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 2, 2016

Primary Completion (Actual)

April 30, 2019

Study Completion (Actual)

April 30, 2019

Study Registration Dates

First Submitted

June 8, 2017

First Submitted That Met QC Criteria

June 8, 2017

First Posted (Actual)

June 9, 2017

Study Record Updates

Last Update Posted (Actual)

November 30, 2022

Last Update Submitted That Met QC Criteria

November 25, 2022

Last Verified

November 1, 2022

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • MR/UCH/FMC/73247

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Intervention Study

Clinical Trials on Medication reconciliation

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uzbekistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe